MARKETS.

The one thing about blockbusters? They often cost more than they should. And they can be hard to access, reliably. We intend to supply plant-based versions of carefully evaluated, carefully chosen, and established market blockbuster biosimilars. Our main revenue stream is expected to originate here, where identical plant-based supplies will be contracted and made available for Phase I and II studies pre-patent expiration and significant revenue post-patent expiration.  A less expensive and more accessible supply of already proven market blockbusters.

Phylloceuticals can fill gaps in current drug manufacturing. Typical manufacturing facilities, with exorbitant capital start-up or renovation costs, are also extremely inflexible, with no nimbleness to supply ever-changing needs.  Phylloceuticals will partner with traditional pharma to offer a more modular, nimbler, less expensive option for biosimilars. Our technology will make it feasible to send drugs to underserved areas.

Phylloceuticals technology makes switching from one therapeutic to another a matter of weeks, rather than months. To produce a new protein, we simply produce more plants. Thus, the switchability factor for pandemic or military vaccine production is achievable, rather than the massive, slow and inflexible orientation of today’s stainless steel bioreactor based mammalian cell culture facilities.

Scalability is a unique selling point here at Phylloceuticals. We can produce massive quantities or micro-scale operations affordably, which makes us unique. This opens opportunities for point-of-care delivery, solving issues related to drug shortages and unpredictable demand in healthcare systems. It also results in equitable distribution of therapeutics. Our system provides a valuable service to healthcare systems for distributed manufacturing. This sets us apart from other big players. When therapeutic healthcare systems struggle to predict demand for key medicine needs, Phylloceuticals can help. 

Small quantities are often needed when patient populations are small. This is a big risk and impractical for traditional manufacturing to spend capital dollars on a facility that will satisfy only a specific patient need and then often sit idle. Using plants as the bioreactor to produce proteins means easy switching and scaleability, perfectly suited for rare, ultra-rare and novel, or orphan drug production.

There is increasing demand from national and regional healthcare systems to secure their own supplies of needed medicine. The Phylloceuticals approach is easily installed, then portable and easy-switch for changing to other, more critically needed therapeutics. This is the future - local production, made easier.